AstraZeneca Pharma India's EBIT per Share for the
three
months ended in Mar. 2026 was ₹24.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹102.68.
During the past 12 months, the average EBIT per Share Growth Rate of AstraZeneca Pharma India was 9.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 16.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for AstraZeneca Pharma India's EBIT per Share or its related term are showing as below:
NSE:ASTRAZEN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.7 Med: 15 Max: 79.5
Current: 16.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AstraZeneca Pharma India was 79.50% per year. The lowest was -41.70% per year. And the median was 15.00% per year.
NSE:ASTRAZEN's 3-Year EBIT Growth Rate is ranked better than 63.16% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs NSE:ASTRAZEN: 16.20
AstraZeneca Pharma India (NSE:ASTRAZEN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
AstraZeneca Pharma India EBIT per Share Related Terms
AstraZeneca Pharma India EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹102.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a EBIT per Share of ₹102.68 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AstraZeneca Pharma India and its competitors. According to the industry distribution chart, AstraZeneca Pharma India ranks #298 out of 809 companies in the Drug Manufacturers industry, placing it in the top 36.8%.
Is AstraZeneca Pharma India's EBIT per Share too high?
AstraZeneca Pharma India's current EBIT per Share is ₹102.68. Based on the distribution chart, AstraZeneca Pharma India ranks #298 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #298 out of 809 companies for EBIT per Share. This puts AstraZeneca Pharma India in the upper half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current EBIT per Share is ₹102.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,922.11, compared to a current price of ₹8,310.50 — trading 23.9% below its estimated fair value. The current EBIT per Share is ₹102.68. AstraZeneca Pharma India's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current EBIT per Share is ₹102.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,310.50 is trading 23.9% below its estimated GF Value™ of ₹10,922.11.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
EBIT per Share: ₹102.68
GF Value™: ₹10,922.11 vs. price of ₹8,310.50 (23.9% below fair value)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
93GF Score
Get the complete analysis for NSE:ASTRAZEN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
